May 25th 2023
Pembrolizumab plus chemotherapy with or without bevacizumab yields a survival benefit in PD-L1 positive patients with cervical cancer in the phase 3 KEYNOTE-826 trial.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
The 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
Community Practice Connections®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
European Commission Approves Cemiplimab for Recurrent/Metastatic Cervical CancerNovember 23rd 2022
The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.
Vaccine-Chemoradiotherapy Combo Produces 100% Clinical Response in Advanced Cervical CancerNovember 15th 2022
Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.
High-Quality Radiotherapy Delivery Not Affected by Durvalumab in High-Risk Locally Advanced Cervical CancerOctober 26th 2022
Data from the phase 3 CALLA trial indicated that multidisciplinary collaboration and a good quality control strategy are key to providing optimal chemoradiotherapy delivery in locally advanced cervical cancer.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and MoreOctober 2nd 2022
Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
Durvalumab Plus CRT Fails to Meet PFS End Point in High-Risk Locally Advanced Cervical CancerSeptember 30th 2022
Results from the phase 3 CALLA trial indicated that durvalumab in combination with chemoradiotherapy did not yield a meaningful improvement in progression-free survival compared with chemoradiotherapy alone in high-risk locally advanced cervical cancer.
Nivolumab ± Ipilimumab Yields Meaningful, Durable Responses in Recurrent or Metastatic Cervical CancerSeptember 28th 2022
The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.
Cemiplimab as Second-Line Monotherapy Confers Long-Term Survival Benefit in Recurrent/Metastatic Cervical CancerSeptember 10th 2022
Findings from long-term follow-up of the EMPOWER-Cervical 1 study demonstrated that cemiplimab improved survival vs chemotherapy and resulted in a safety profile like other anti–PD-L1 agents.
Local Treatment Choice for Cervical Intraepithelial Neoplasia and Stage IA1 Cervical Cancer Appears to Influence Efficacy, Risk of Preterm BirthAugust 19th 2022
In a population of patients with cervical intraepithelial neoplasia and stage IA1 cervical cancer, certain local treatments, such as radical excision and ablation, were associated with treatment outcomes and risk of preterm birth.
Pembrolizumab Plus Chemotherapy With or Without Bevacizumab Consistently Improves Survival in Advanced Cervical Cancer SubgroupsJune 6th 2022
Results from the phase 3 KEYNOTE-826 trial show a significant survival benefit with pembrolizumab plus chemotherapy with or without bevacizumab in most patient subgroups with persistent, recurrent, or metastatic cervical cancer.
European Commission Approves Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Cervical CancerMay 3rd 2022
Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.
Jyoti S. Mayadev, MD, on Atezolizumab for Locally Advanced, Node-Positive Cervical CancerApril 7th 2022
At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.
Jyoti Mayadev, MD, Provides Perspective on Atezolizumab in Locally Advanced Cervical CancerMarch 28th 2022
At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.
Patient-Reported Outcomes Provide Additional Support for Pembrolizumab Combo in First-Line Cervical CancerMarch 19th 2022
Updated results from the KEYNOTE-826 study show a favorable risk-benefit ratio for pembrolizumab plus chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.
Clinical Trial for Patients With Previously Treated Recurrent or Metastatic Cervical Cancer Is Exploring Ociperlimab Plus Tislelizumab ComboMarch 19th 2022
An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.
Pembrolizumab Prolongs Survival Over Placebo for Persistent, Recurrent, or Metastatic Cervical CancerFebruary 9th 2022
Pembrolizumab for patients with persistent, recurrent, or metastatic cervical cancer who received chemotherapy with or without bevacizumab had longer progression-free and overall survival vs placebo-treated patients.
Cemiplimab Biologics License Application for Advanced Cervical Cancer Withdrawn Following Discourse With FDAJanuary 30th 2022
In a regulatory update on cemiplimab for advanced cervical cancer, Regeneron Pharmaceuticals announced that the agent’s biologics license application has been withdrawn.
Second-Line Balstilimab Plus Zalifrelimab Yields Durable Clinical Activity in Recurrent/Metastatic Cervical CancerJanuary 7th 2022
Findings from a phase 2 study demonstrated encouraging clinical activity and a manageable safety profile when patients with advanced cervical cancer were treated with second-line balstilimab and zalifrelimab.
Low Socioeconomic Status New York City Neighborhoods Associated With Cervical Cancer Incidence DisparitiesDecember 29th 2021
Cervical cancer incidence rates were significantly higher in the lowest-socioeconomic status neighborhoods vs the highest-socioeconomic status neighborhoods in New York City.
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced CancersNovember 16th 2021
Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities
In this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Cervical Cancer and Grade 3 Cervical Intraepithelial Neoplasia Incidence Reduced in Young, HPV-Vaccinated IndividualsNovember 4th 2021
Those immunized between the ages of 12 and 13 in England experienced a significant estimated reduction in cervical cancer and grade 3 cervical intraepithelial neoplasia incidence rates compared with unvaccinated women.
Cemiplimab Receives Priority Review From the FDA In Recurrent or Metastatic Cervical CancerOctober 4th 2021
Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.